A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Summary

This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first line setting or have disease relapse after receiving cisplatin based chemotherapy within a year in the neoadjuvant or adjuvant setting.

Timeline

Start

2018-10-29

Primary completion

2021-12-15

Completion

2024-02-09

Publications

• Garje R, Ravindra A, Rahim B, Kroll M, Johnson JS, Torres J, Bonner J, Packiam VT, Mott S, O'Donnell M, Zakharia Y. Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial). Urol Oncol. 2025 Sep;43(9):520.e9-520.e18. doi: 10.1016/j.urolonc.2025.04.005. Epub 2025 May 31.

Drugs

Indications